Human uterine and ovarian expression of growth hormone-releasing hormone messenger RNA in benign and malignant gynecologic conditions

被引:41
|
作者
Khorram, O [1 ]
Garthwaite, M [1 ]
Grosen, E [1 ]
Golos, T [1 ]
机构
[1] Univ Wisconsin, Dept Obstet & Gynecol, Madison, WI 53706 USA
关键词
growth hormone-releasing hormone; endometrium; ovary; endometriosis; endometrial cancer; ovarian cancer;
D O I
10.1016/S0015-0282(00)01658-7
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To determine uterine and ovarian expression of growth hormone-releasing hormone (GHRH) messenger RNA (mRNA) in benign and pathologic gynecologic states. Design: Case-control study. Setting: Tertiary-care academic department. Patient(s): Women undergoing hysterectomy for benign or malignant gynecologic conditions. Intervention(s): Ovarian and uterine tissue was obtained for measurement of GHRH mRNA levels by reverse transcription polymerase chain reaction. Main Outcome Measure(s): Levels of GHRH mRNA in normal tissues were compared with those in tissues with pathologic abnormalities. Result(s): Growth hormone-releasing hormone mRNA was detectable in the ovary, endometrium, myometrium, fallopian tubes, and placenta. Levels of GHRH mRNA were significantly increased in secretory endometrium compared with proliferative endometrium. Hormone replacement therapy did not affect endometrial GHRH mRNA levels. Uterine myomas expressed similar levels of GHRH mRNA as normal myometrium. No changes in endometrial GHRH mRNA were detected in endometrial cancers compared with normal endometrium or myometrium obtained from the same patient; however, these levels were higher than those in noncancerous myometrial tissue obtained from other patients with benign gynecologic disease. In ovarian tissue, no differences in GHRH mRNA were found between premenopausal and postmenopausal women. Ovarian GHRH mRNA was significantly decreased in endometriotic cysts, whereas significantly greater GHRH expression occurred in ovarian cancer compared with normal ovarian tissue. Conclusion(s): Endometrial and ovarian GHRH gene transcription are altered in selective physiologic and pathologic states and are influenced by such factors as ovarian hormones, Because it is a growth factor, GHRH may promote endometrial proliferation and may be involved in the pathogenesis of ovarian and endometrial cancer and endometriosis. (C) 2001 by American Society for Reproductive Medicine.
引用
收藏
页码:174 / 179
页数:6
相关论文
共 50 条
  • [41] ALTERATIONS OF ADENYLYL CYCLASE-COUPLED GROWTH HORMONE-RELEASING HORMONE (GHRH) PITUITARY RECEPTORS IN DIFFERENT CONDITIONS OF GHRH DEPRIVATION
    QING, Y
    PARENTI, M
    GUZZI, F
    CERESOLI, G
    MULLER, EE
    COCCHI, D
    BRAIN RESEARCH, 1994, 644 (01) : 13 - 18
  • [42] Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207
    Arencibia, JM
    Bajo, AM
    Schally, AV
    Krupa, M
    Chatzistamou, I
    Nagy, A
    ANTI-CANCER DRUGS, 2002, 13 (09) : 949 - 956
  • [43] Vasoactive intestinal polypeptide mRNA and peptide levels are decreased in the anterior pituitary of the human growth hormone-releasing hormone transgenic mouse
    Hyde, JF
    Morrison, DG
    Drake, KW
    Moore, JP
    Maley, BE
    JOURNAL OF NEUROENDOCRINOLOGY, 1996, 8 (01) : 9 - 15
  • [44] Effects of adrenalectomy and glucocorticoid receptor antagonist, RU38486, on pituitary growth hormone-releasing hormone receptor gene expression in rats
    Ohyama, T
    Sato, M
    Ohye, H
    Murao, K
    Niimi, M
    Takahara, J
    PEPTIDES, 1998, 19 (06) : 1063 - 1067
  • [45] Suppression of the proliferation of human U-87 MG glioblastoma cells by new antagonists of growth hormone-releasing hormone in vivo and in vitro
    Miklos Jaszberenyi
    Andrew V. Schally
    Norman L. Block
    Marta Zarandi
    Ren-Zhi Cai
    Irving Vidaurre
    Luca Szalontay
    Arumugam R. Jayakumar
    Ferenc G. Rick
    Targeted Oncology, 2013, 8 : 281 - 290
  • [46] Suppression of the proliferation of human U-87 MG glioblastoma cells by new antagonists of growth hormone-releasing hormone in vivo and in vitro
    Jaszberenyi, Miklos
    Schally, Andrew V.
    Block, Norman L.
    Zarandi, Marta
    Cai, Ren-Zhi
    Vidaurre, Irving
    Szalontay, Luca
    Jayakumar, Arumugam R.
    Rick, Ferenc G.
    TARGETED ONCOLOGY, 2013, 8 (04) : 281 - 290
  • [47] Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness
    Arencibia, JM
    Schally, AV
    Krupa, M
    Bajo, AM
    Nagy, A
    Szepeshazi, K
    Plonowski, A
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2001, 19 (03) : 571 - 577
  • [48] SEQUENCE AND EXPRESSION OF CDNA FOR PITUITARY ADENYLATE-CYCLASE ACTIVATING POLYPEPTIDE (PACAP) AND GROWTH HORMONE-RELEASING HORMONE (GHRH)-LIKE PEPTIDE IN CATFISH
    MCRORY, JE
    PARKER, DB
    NGAMVONGCHON, S
    SHERWOOD, NM
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1995, 108 (1-2) : 169 - 177
  • [49] Ovarian expression of messenger RNA encoding the receptors for luteinizing hormone and follicle-stimulating hormone in a marsupial, the brushtail possum (Trichosurus vulpecula)
    Eckery, DC
    Lun, S
    Thomson, BP
    Chie, WN
    Moore, LG
    Juengel, JL
    BIOLOGY OF REPRODUCTION, 2002, 66 (05) : 1310 - 1317
  • [50] Growth hormone-releasing hormone antagonist induces apoptosis of human endometrial cancer cells through PKCδ-mediated activation of p53/p21
    Wu, Hsien-Ming
    Schally, Andrew V.
    Cheng, Jung-Chien
    Zarandi, Marta
    Varga, Jozsef
    Leung, Peter C. K.
    CANCER LETTERS, 2010, 298 (01) : 16 - 25